Is a severely damaged Biogen looking to shed its ties to a controversial development partner?

After taking it on the chin throughout Thursday and Friday for its questionable strategy of sticking with the amyloid beta theory on Alzheimer’s — topped by the news that its partner Eisai had picked one of the worst moments possible to launch a new Phase III trial of their other Alzheimer’s drug BAN2401 — Biogen ended the week with a statement that stopped far short of a ringing endorsement of the move by their collaborators.